I think its safe to say NEU management when negotiating the deal would have gone over all possible scenarios with regard to Nuplazids prospects and the possible implications for Trofinatide p3 trials.
They were obviously comfortable with it, although like others have said it would be good to get some clarification from management.
Ann: Change of Director's Interest Notice, page-17
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
0.000(0.00%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 814 | $14.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.92 | 64 | 1 |
View Market Depth
| Last trade - 10.03am 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable